RPAY

Current Thesis

Event-driven special-sit: two activists (Forager Capital + Veradace Partners) are pressing the board to abandon the KUBRA acquisition and sell the company. Forager put a $4.80 cash bid on the table 2026-04-17; board responded 2026-04-14 with a poison pill after "large accumulation." Trade is binary arb — topped bid / strategic emerges / deal gets done at $5.25–$6.00+ vs. the activists walk and stock round-trips to pre-ramp ($3.20–$3.60). The $4.80 floor is not firm (non-binding, no financing disclosed), but the pressure is real and multi-activist.

Bull Case

• 2026-04-17 Forager bid: unsolicited non-binding cash offer at $4.80/sh — sets a visible floor/anchor that strategic acquirers (Global Payments, Shift4, Nuvei, PE-backed payments platforms) now have to beat.
• 2026-04-09 Veradace open letter: second activist demanding abandonment of KUBRA deal and board refresh. Two independent activists converging = sale-process probability materially higher than single-activist base rate (~60–70% resolution within 6–9 months per historical micro-cap activism datasets).
• 2026-04-14 poison pill: classic negotiating playbook. Boards adopt pills not to kill deals but to force bidders to negotiate and allow process to surface multiple buyers. Signals board expects more interest.
• Payments consolidation narrative: sub-scale processors at <1x sales have been consolidation targets all cycle (PAY, Paysafe, EVO). RPAY fits the template — ~$300M rev, verticalized (consumer finance, healthcare, B2B AR), sticky integrations.
• Capital structure friendly to LBO: asset-light, recurring revenue, convertible notes but no punishing secured debt wall. PE math works at $5.25–$5.75.

Bear Case

• Forager is small: not a Starboard/Elliott. Financing is unconfirmed, bid is non-binding. Board can slow-walk without real consequence if no strategic shows.
• $4.80 may be a ceiling, not a floor: if no topping bid materializes in 4–6 weeks, Forager either walks or lowers. Stock that gapped to ~$4.50–$4.70 retraces to $3.40–$3.80 pre-event level = ~25–30% downside from post-ramp.
• KUBRA deal is the real risk: if board pushes KUBRA transaction through (scrip or debt-funded), they dilute/lever the company specifically to make it harder to take private. That's the Veradace fear, and it's a legitimate one.
• Poison pill cuts both ways: it also signals board WILL fight. If they genuinely believe KUBRA-integrated RPAY is worth >$6, they'll stall.
• No Q1 catalyst support: nothing on the fundamentals calendar forces hands before Aug earnings.
• Payments sector multiples still compressed: comps trading 6–9x EBITDA; $4.80 is already inside reasonable-deal range. Limited room to squeeze 20% more.

Setup & Price Structure

• Pre-activism price range (Feb–early Apr 2026): roughly $3.20–$3.80.
• 2026-04-14 poison-pill news + 2026-04-17 Forager bid → stock "soaring" — expected gap into $4.40–$4.70, clustering under the $4.80 bid ceiling (typical deal-stub behavior: ~5–8% discount to bid reflects close probability × time).
• Classic event-driven structure: price pins under the offer, volume spikes, IV on short-dated calls explodes. This is NOT a momentum chart — reading 20-EMA/RSI is the wrong lens.
• Key levels:
• $4.80 = Forager anchor (ceiling unless topped)
• $4.40–$4.55 = typical deal-arb zone (5–8% under bid)
• $3.80 = pre-bid resistance → becomes support if deal breaks
• $3.20 = full round-trip to pre-activism base
• Risk/reward from [entry redacted] entry: ~[entry redacted] upside to [entry redacted] topped bid / ~$1.10 downside to $3.40 if deal dies = ~0.7:1 nominal, juiced to ~2:1 if you assign 60% prob of deal-adjacent outcome. Not a fat pitch at current levels.

Catalyst Calendar (next 30 days)

• ~2026-04-24 to 2026-05-01 (est.): Board's formal response to Forager $4.80 bid. Reject / engage / request improvement. Primary binary.
• ~2026-05-08 (est.): Deadline window for Forager to raise bid or walk if board rejects (typical activist cadence).
• ~2026-05-15 (est.): Possible KUBRA deal update — if board files proxy materials, Veradace escalation likely (proxy fight threat).
• ~2026-05-12 to 2026-05-20 (est.): 13D/A amendments from Forager and/or Veradace — watch for new holders joining the block.
• Q1 2026 earnings: historically early-to-mid August — NOT a 30-day catalyst. No fundamental binary this window.

What Would Change Our Mind

Upgrade to HIGH/SUPREME if:

• A second bidder emerges (strategic or PE) at ≥$5.20 — confirms sale process and re-rates odds.
• Board publicly engages Forager / forms special committee — signals willingness to transact.
• Third activist 13D filed — cascade dynamic, board loses control.

Downgrade to SKIP / exit if:

• Forager withdraws the proposal (any press release with "no longer pursuing" language) — thesis dead, gap down to $3.40.
• Board closes KUBRA deal on current terms without activist concessions — dilutes optionality, signals board won.
• Stock closes two consecutive sessions below $4.15 on volume — market pricing in deal failure before news.
• 30+ days pass with no board response — indicates stonewalling, Forager walks.

Correlation Notes

• Theme: m-and-a-activism-special-sits — primary. Behaves differently from momentum book; adds zero beta drag.
• Payments sector comps (GPN, FOUR, PAY, NVEI): RPAY trades on deal-specific dynamics now, decorrelated from sector tape unless sector sell-off drags multiples and kills PE math.
• Activism cluster: correlated with other active multi-activist small-caps (watch for similar setups — this cohort tends to resolve in waves).
• Macro sensitivity: very LOW while bid is live. HIGH if deal breaks (risk-off tape = harder to restart process).
• Archetype discipline: this is a5 Binary Catalyst — size modestly (1.5–2.5% gross), use stops at deal-break level ($4.15), do NOT average down if stock drifts to $4.20. Event-driven trades are NOT momentum trades; trim rules (RSI>75, 20-EMA break) do not apply. Exit triggers are news-driven or level-driven at $4.15.

---

Operator read: Interesting setup, not urgent. Gap already happened 2026-04-17. [entry redacted]–$4.60 with stop [entry redacted] is a defensible probe (LOW-MEDIUM sizing). Fat pitch would require a dip back to $4.20–$4.30 on "no board response yet" noise, or a second bidder print that confirms process. Current state: ACCELERATING (new bid, pill, two activists) but already partially priced. Wait for board response or a pullback. Don't chase the post-announcement pop.